Autopsies Revealed Pathological Features of COVID-19 in Unvaccinated vs. Vaccinated Patients

Abstract Background: In Italy, by the end of 2021, a new pandemic wave led to increased hospitalizations and death, even in some vaccinated people. We aimed to investigate the death of COVID-19-vaccinated patients who acquired infection and developed severe disease, and to assess differences with fatal COVID-19 in unvaccinated subjects by studying the pathological events triggered by SARS-CoV-2. Methods: Detailed autoptic examination was performed on five fully vaccinated compared to five unvaccinated patients. Histopathological analysis focused on the lung and heart, the two major affected organs. Results: COVID-19 caused, or contributed to death, in all the unvaccinated cases. By contrast, in vaccinated group, pre-existing pathologies played a major role, and death was not COVID-19-related in four out of five patients. These patients did not show the histological features of SARS-CoV-2 lung damage. Diffuse inflammatory macrophages infiltration recently emerged as the main feature of COVID-19 cardiac injury. Interestingly, the most striking difference between the two groups was the absence of increased macrophage infiltration in the heart of vaccinated patients. Conclusions: Results of this study confirm the efficacy of anti-SARS-CoV-2 vaccination in protecting organs from injury and support the need to maintain an adequate immune response by booster dose administration.

[1]  S. Pittaluga,et al.  SARS-CoV-2 infection and persistence in the human body and brain at autopsy , 2022, Nature.

[2]  P. Maes,et al.  Author Correction: Organ-specific genome diversity of replication-competent SARS-CoV-2 , 2022, Nature Communications.

[3]  A. Trimaille,et al.  Cardiovascular manifestations secondary to COVID-19: A narrative review , 2022, Respiratory Medicine and Research.

[4]  T. Alexy,et al.  COVID-19-Associated Myocarditis: An Evolving Concern in Cardiology and Beyond , 2022, Biology.

[5]  P. Boor,et al.  INFLAMMATION AND VASCULAR REMODELING IN COVID-19 HEARTS , 2022, Journal of the American College of Cardiology.

[6]  Y. Ladilov,et al.  Cardiovascular Inflammaging: Mechanisms and Translational Aspects , 2022, Cells.

[7]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[8]  G. Bonnet,et al.  Cardiovascular Characteristics and Outcomes of Young Patients with COVID-19 , 2021, Journal of cardiovascular development and disease.

[9]  D. Beiser,et al.  Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel , 2021, The New England journal of medicine.

[10]  R. Nardacci,et al.  Neuropathology and Inflammatory Cell Characterization in 10 Autoptic COVID-19 Brains , 2021, Cells.

[11]  A. Chinnaiyan,et al.  Characterization of SARS-CoV-2 and host entry factors distribution in a COVID-19 autopsy series , 2021, Communications Medicine.

[12]  Lauren E. W. Olsho,et al.  Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines , 2021, The New England journal of medicine.

[13]  M. Catálfamo,et al.  Editorial: The Interplay Between Immune Activation and Cardiovascular Disease During Infection, Autoimmunity and Aging: The Role of T Cells , 2021, Frontiers in Immunology.

[14]  P. Boor,et al.  Multisystemic Cellular Tropism of SARS-CoV-2 in Autopsies of COVID-19 Patients , 2021, medRxiv.

[15]  G. Zimmerman,et al.  COVID-19–Associated Acute Respiratory Distress Syndrome , 2021, Critical Care Clinics.

[16]  P. Austin,et al.  Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study , 2021, BMJ.

[17]  E. Sprecher,et al.  Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers. , 2021, JAMA.

[18]  D. Swerdlow,et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.

[19]  T. Luedde,et al.  Secondary sclerosing cholangitis as a complication of severe COVID‐19: A case report and review of the literature , 2021, Clinical case reports.

[20]  A. Antinori,et al.  Hepatic Failure in COVID-19: Is Iron Overload the Dangerous Trigger? , 2021, Cells.

[21]  C. Newton-Cheh,et al.  Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19 , 2021, Modern Pathology.

[22]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[23]  L. Pantanowitz,et al.  Postmortem Findings Associated With SARS-CoV-2 , 2021, The American journal of surgical pathology.

[24]  M. Aepfelbacher,et al.  Neuropathology of patients with COVID-19 in Germany: a post-mortem case series , 2020, The Lancet Neurology.

[25]  A. Tzankov,et al.  Hunting coronavirus by transmission electron microscopy – a guide to SARS‐CoV‐2‐associated ultrastructural pathology in COVID‐19 tissues , 2020, Histopathology.

[26]  S. Rizzo,et al.  Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study , 2020, European heart journal.

[27]  G. Ippolito,et al.  Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities , 2020, The Journal of infectious diseases.

[28]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[29]  Srinivas Murthy,et al.  Care for Critically Ill Patients With COVID-19. , 2020, JAMA.

[30]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[31]  G. Pawelec,et al.  Age and immunity: What is “immunosenescence”? , 2017, Experimental Gerontology.

[32]  A. Eriksson,et al.  Multivariate linear regression modelling of lung weight in 24,056 Swedish medico-legal autopsy cases. , 2017, Journal of forensic and legal medicine.

[33]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[34]  D Kimberley Molina,et al.  Normal Organ Weights in Men: Part II—The Brain, Lungs, Liver, Spleen, and Kidneys , 2012, The American journal of forensic medicine and pathology.

[35]  K. Arakawa,et al.  Chronic variant of myocarditis associated with hepatitis C virus infection. , 1997, Circulation.

[36]  W. Whimster,et al.  Normal lung weights in a white population. , 2015, The American review of respiratory disease.